undamentalytics Newsletter
Sign in

Pavmed Inc. income statement

In fiscal 2025, Pavmed Inc. reported revenue of $71,000, down 97.6% on the year before, operating income of −$21.8m (a -30712.7% margin) and net income of $401,000, or −$5.63 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue103300
Cost of revenue146500
Gross profit−0−3−4−2−0−0
Research and development202514646
Selling and marketing919181211
General and administrative254131251619
Operating income−54−91−69−44−22−27
Interest expense—11000
Income before tax−56−103−7928−2−16
Income tax———00—
Net income−50−89−64400−12
Diluted EPS−$9.75−$15.03−$9.16$14.90−$5.63—
Diluted shares (average)5m6m7m2m——
EBITDA−54−89−66−43−22−27

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: PAVM vs POASNXL vs PAVMPAVM vs QTEXCUPR vs PAVM

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Pavmed Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pavmed Inc.